申请人:Dainippon Pharmaceutical Co., Ltd.
公开号:US04870074A1
公开(公告)日:1989-09-26
Compounds of the formula: ##STR1## wherein R is hydrogen, alkoxycarbonyl, benzyloxycarbonyl, heteroarylalkyl, phenylalkenyl, or --T--(Y).sub.p --R.sub.6 (wherein T is single bond or alkylene, Y is oxygen, sulfur or carbonyl, R.sub.6 is phenyl, substituted phenyl, naphthyl, or diphenylmethyl, and p is 0 or 1, provided that when T is single bond, p is 0); R.sub.1 is halogen, hydroxy, alkoxy, cycloalkyloxy, alkenyloxy, alkynyloxy, alkoxy interrupted by oxygen or carbonyl, alkylthio, amino, monosubstituted amino, or a substituted alkoxy; R.sub.2 is hydrogen; R.sub.3 is hydrogen, halogen, amino, alkylamino, dialkylamino, alkanoylamino, or nitro; R.sub.4 is hydrogen, halogen, nitro, sulfamoyl, alkylsulfamoyl, or dialkylsulfamoyl; or any two adjacent groups of the R.sub.1, R.sub.2, R.sub.3 and R.sub.4 may combine to form alkylenedioxy, and the remaining two groups are each hydrogen; R.sub.5 is hydrogen or alkyl; X is alkylene; m and n are each 1 or 2; provided that at least one of the groups R.sub.2, R.sub.3 and R.sub.4 is other than hydrogen, and acid addition salts, quaternary ammonium salts and N-oxide derivatives thereof, processes for preparation thereof, and pharmaceutical composition containing the same. Said compounds, salts and N-oxide derivatives thereof show excellent gastrointestinal motility enhancing activity.
式中R为氢、烷氧羰基、苄氧羰基、杂环烷基、苯基烯基,或--T--(Y).sub.p --R.sub.6(其中T为单键或烷基,Y为氧、硫或羰基,R.sub.6为苯基、取代苯基、萘基或二苯甲基,p为0或1,但当T为单键时,p为0);R.sub.1为卤素、羟基、烷氧基、环烷氧基、烯基氧基、炔基氧基、被氧或羰基中断的烷氧基、烷基硫醚、氨基、单取代氨基,或取代烷氧基;R.sub.2为氢;R.sub.3为氢、卤素、氨基、烷基氨基、二烷基氨基、烷酰氨基,或硝基;R.sub.4为氢、卤素、硝基、磺酰胺基、烷基磺酰胺基,或二烷基磺酰胺基;或R.sub.1、R.sub.2、R.sub.3和R.sub.4中的任意两个相邻基团可结合形成亚烷二氧基,其余两个基团各为氢;R.sub.5为氢或烷基;X为烷基;m和n各为1或2;但R.sub.2、R.sub.3和R.sub.4中至少有一个基团不是氢,以及其酸盐、季铵盐和N-氧化物衍生物,其制备方法,以及含有它们的药物组合物。所述化合物、盐及其N-氧化物衍生物表现出优异的胃肠动力增强活性。